(Q42937632)

English

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

scientific article published on 12 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). (English)

1 reference

Europe PubMed Central

11 November 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Narikazu Boku

1 reference

Europe PubMed Central

11 November 2017

Ichinosuke Hyodo

18

object named as

Ichinosuke Hyodo

1 reference

Europe PubMed Central

11 November 2017

author name string

Kei Muro

1

1 reference

Europe PubMed Central

11 November 2017

Yasuhiro Shimada

3

1 reference

Europe PubMed Central

11 November 2017

Akihito Tsuji

4

1 reference

Europe PubMed Central

11 November 2017

Shinichi Sameshima

5

1 reference

Europe PubMed Central

11 November 2017

Hideo Baba

6

1 reference

Europe PubMed Central

11 November 2017

Taroh Satoh

7

1 reference

Europe PubMed Central

11 November 2017

Tadamichi Denda

8

1 reference

Europe PubMed Central

11 November 2017

Kenji Ina

9

1 reference

Europe PubMed Central

11 November 2017

Tomohiro Nishina

10

1 reference

Europe PubMed Central

11 November 2017

Kensei Yamaguchi

11

1 reference

Europe PubMed Central

11 November 2017

Hiroya Takiuchi

12

1 reference

Europe PubMed Central

11 November 2017

Taito Esaki

13

1 reference

Europe PubMed Central

11 November 2017

Shinya Tokunaga

14

1 reference

Europe PubMed Central

11 November 2017

Hiroyuki Kuwano

15

1 reference

Europe PubMed Central

11 November 2017

Yoshito Komatsu

16

1 reference

Europe PubMed Central

11 November 2017

Masahiko Watanabe

17

1 reference

Europe PubMed Central

11 November 2017

Satoshi Morita

19

1 reference

Europe PubMed Central

11 November 2017

Kenichi Sugihara

20

1 reference

Europe PubMed Central

11 November 2017

publication date

12 August 2010

1 reference

Europe PubMed Central

11 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

11 November 2017

11

1 reference

Europe PubMed Central

11 November 2017

9

1 reference

Europe PubMed Central

11 November 2017

853-860

1 reference

Europe PubMed Central

11 November 2017

Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(10)70181-9

1 reference

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42937632&oldid=1886759347"